Swami, O., Sharma, S. K., Panneerselvam, A., Singh, K. P., Parmar, G., & Gadge, P. (2016). Teneligliptin in management of type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity, Volume 9, 251–260. https://doi.org/10.2147/dmso.s106.
Reference ID: 4079189, FDA reference, GLUCOPHAGE. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf
Zhu, M., Guan, R., & Ma, G. (2023). Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis. Frontiers in endocrinology, 14, 1282584. https://doi.org/10.3389/fendo.2023.1282584
Ji, L., Li, L., Ma, J., Li, X., Li, D., Meng, B., Lu, W., Sun, J., Liu, Y., Takayanagi, G., & Wang, Y. (2021). Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study. Endocrinology, diabetes & metabolism, 4(2), e00222. https://doi.org/10.1002/edm2.222
Kim, M. K., Rhee, E. J., Han, K. A., Woo, A. C., Lee, M. K., Ku, B. J., Chung, C. H., Kim, K. A., Lee, H. W., Park, I. B., Park, J. Y., Chul Jang, H. C., Park, K. S., Jang, W. I., & Cha, B. Y. (2015). Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes, obesity & metabolism, 17(3), 309–312. https://doi.org/10.1111/dom.12424